In another shocker, FDA rejects BioMarin’s hemophilia A gene therapy, demanding more data on durability

John Carroll

Editor & Founder

It turns out that BioMarin’s rivals aren’t the only ones with doubts about the durability of BioMarin’s hemophilia A gene therapy. Regulators at the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

In another shocker, FDA rejects BioMarin’s hemophilia A gene therapy, demanding more data on durability

John Carroll

Editor & Founder

Sign up to read this article for free.

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

Advocacy groups and experts call for decade-long ban on germline editing

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

CRISPR patent spat revived by federal appeals court ruling

In an­oth­er shock­er, FDA re­jects Bio­Marin’s he­mo­phil­ia A gene ther­a­py, de­mand­ing more da­ta on dura­bil­i­ty

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

In another shocker, FDA rejects BioMarin’s hemophilia A gene therapy, demanding more data on durability

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

Advocacy groups and experts call for decade-long ban on germline editing

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

CRISPR patent spat revived by federal appeals court ruling